AstraZeneca has announced that Axanum, a fixed dose combination of 81mg low-dose aspirin and 20 mg esomeprazole, has received positive agreement for approval in 23 European Union member countries and in Norway. Axanum is indicated for prevention of cardiovascular (CV) events in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers.